Atlantic Healthcare has completed patient enrolment in a Phase III trial of alicaforsen to treat patients with IBD pouchitis.

The randomised, double-blind, placebo-controlled trial expects to evaluate the safety and efficacy of alicaforsenas in enema formulation.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial has enrolled patients who have previously undergone colectomy to remove the colon due to failure of drug therapy for ulcerative colitis (UC), and have then undergone ileal pouch-anal anastomosis (IPAA) surgery to create a new rectum.

“This is another important milestone in assessing the clinical value of alicaforsen in this setting.”

Phase III trial chief investigator Brian Feagan said: “This is another important milestone in assessing the clinical value of alicaforsen in this setting, a rare disease believed to impact the lives of approximately 200,000 patients in the US and Europe, for which there remains a critical unmet clinical need.”

Under the trial, the patients were randomised one-to-one to receive 240mg of alicaforsen enema or placebo at 40 sites across the US, Canada, Europe and Israel.

The patients self-administered the prescribed doses of alicaforsen and placebo daily for six weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial’s co-primary endpoints are improvement in endoscopic healing and reduction in bowel frequency at week ten, while its secondary endpoints include improvement in other symptoms of the disease and quality of life.

Patients in the trial are monitored for up to six months after treatment.

Atlantic plans to conclude the trial and report preliminary results by the first quarter of next year.

IBD pouchitiss is a rare and serious form of inflammatory bowel disease (IBD), which has limited treatment options.

There is currently no approved therapy available for the disease.